Ruslan M. Paltuev

Ruslan M. Paltuev

Auto-generated profile, based on publicly available information

Ruslan M. Paltuev

N.N. Petrov National Medical Research Oncology Center, Ministry of Health of Russia

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 June 2007 in Cancer
Verified
Journal Article
Closed access
PDF file
VSVladimir F. Semiglazov
Vladimir F. Semiglazov
VSVladislav V. Semiglazov
Vladislav V. Semiglazov
GDGarik A. Dashyan
Garik A. Dashyan
EZElena K. Ziltsova
Elena K. Ziltsova
VIVadim G. Ivanov
Vadim G. Ivanov
LBLev M. Berstein
Lev M. Berstein

8 May 2021 in Cancers
Verified
Journal Article
Open access
PDF file
HEHesham Elghazaly
Hesham Elghazaly
HRHope Rugo
Hope Rugo
HAHamdy A. Azim
Hamdy A. Azim
SSSandra Swain
Sandra Swain
BABanu K. Arun
Banu K. Arun
HEHagar Elghazawy
Hagar Elghazawy
Background: The management of patients with triple-negative breast cancer (TNBC) is challenging with several controversies and unmet needs. During the 12th Breast-Gynaecological & Immuno-oncology International Cancer Conference (BGICC) Egypt, 2020, a panel of 35 breast cancer experts from 13 countries voted on consensus guidelines for the clinical management of TNBC. The consensus was subsequently updated based on the most recent data evolved lately. Methods: A consensus conference approach adapted from the American Society of Clinical Oncology (ASCO) was utilized. The panellists voted anonymously on each question, and a consensus was achieved when ≥75% of voters selected an answer. The final consensus was later circulated to the panellists for critical revision of important intellectual content. Results and conclusion: These recommendations represent the available clinical evidence and expert opinion when evidence is scarce. The percentage of the consensus votes, levels of evidence and grades of recommendation are presented for each statement. The consensus covered all the aspects of TNBC management starting from defining TNBC to the management of metastatic disease and highlighted the rapidly evolving landscape in this field. Consensus was reached in 70% of the statements (35/50). In addition, areas of warranted research were identified to guide future prospective clinical trials.

19 May 2021 in Journal of Modern Oncology
Verified
Journal Article
Open access
PDF file
LZLiudmila Zhukova
Liudmila Zhukova
IAIuliia I. Andreeva
Iuliia I. Andreeva
LZLarisa E. Zavalishina
Larisa E. Zavalishina
AZAziz D. Zakiriakhodzhaev
Aziz D. Zakiriakhodzhaev
IKIrina A. Koroleva
Irina A. Koroleva
НАНевольских Алексей Алексеевич
Невольских Алексей Алексеевич
Breast cancer (BC) is a malignant tumor originating from the epithelium of the breast tissue. There is no single etiological factor in the development of breast cancer. In 310% of patients with breast cancer, the development of the disease is associated with the presence of mutations in the breast cancer gene (BRCA) 1, BRCA2, CHEK, NBS1, TP53. In other patients, breast cancer is sporadic.

1 May 2018 in Voprosy onkologii
Verified
Journal Article
Open access
PDF file
TSTatyana Semiglazova
Tatyana Semiglazova
YTYevgeniya Tsyrlina
Yevgeniya Tsyrlina
APArtem Poltoratskiy
Artem Poltoratskiy
YBYekaterina Busko
Yekaterina Busko
VSVladislav Semiglazov
Vladislav Semiglazov
ЕЖЕлена Жильцова
Елена Жильцова
Materials and methods. The effect of melatonin (MLT) and metformin (MTF) on the efficacy of neoadjuvant hormone therapy with toremifene was investigated in 54 patients with estrogen receptor-positive, locally advanced breast cancer (ER + BC). The average age of women was 67 years. The patients had no diabetes mellitus. The first group of patients (n = 19) received toremifene 120 mg per day, the second group (n = 16) - toremifene in combination with MLT 3 mg orally every night, the third group (n = 19) - toremifene in combination with MTF 850 mg twice daily. Randomization was performed - 1: 1: 1. The duration of therapy in all study groups was 4 months. After the end of treatment, all patients were undergone surgery. Further adjuvant treatment depended on the results of the postoperative pathomorphological conclusion. The primary endpoint was a decrease in the Ki-67% level (a surrogate marker for the effectiveness of hormone therapy), the secondary endpoints were the objective response, a pathological response in the tumor and lymph nodes, and the quality of life. Results. In all patients (n = 54), the frequency of decrease Ki-67 level and the frequency of objective response were 57% and 50%, respectively. At the same time, the incidence of Ki-67% level decrease in the «toremifene» group was 42%, in the «toremifene+MLT» group - 56%, in the «toremifene+MTF» group - 74%. Multifactor analysis showed that the addition of MTF to toremifene increases the chances of reducing Ki-67 compared with control 4.2 times (RR 4.23 [95% CI 1,04417,139], p = 0.043). It is important that only in the patients of the «toremifene+MTF» group a significant correlation was found between the Ki-67 index decrease in the tumor and the BMI value above the norm (p = 0.015). A complete pathomorphological response in the tumor and lymph nodes was not achieved in any patient. The objective response in the study groups was 31.6%, 86.7% and 47.3%, respectively. The addition of MLT to hormone therapy with toremifene significantly increased the frequency of the objective response from 31.6% to 86.7% (x2 = 10.32, p = 0.001). The inclusion into neoadjuvant hormone therapy with toremifene of MLT or MTF did not reduce the quality of life of patients, while in 50% of patients in the «toremifene+MLT» group there was an improvement in sleep.

1 February 2017 in Voprosy onkologii
Verified
Journal Article
Open access
PDF file
ПКПетр Криворотько
Петр Криворотько
KZKonstantin Zernov
Konstantin Zernov
RPRuslan Paltuev
Ruslan Paltuev
АААнна Артемьева
Анна Артемьева
YTYelena Turkevich
Yelena Turkevich
ЕЖЕлена Жильцова
Елена Жильцова
The aim of the study was to evaluate a 3-year distant treatment outcomes of patients with early breast cancer who had undergone sentinel lymph node biopsy. Methods. A total of 681 patients with early cT1-2N0M0 breast cancer treated in the N.N. Petrov research institute of oncology form 2012 till 2016 were retrospectively enrolled in the study. Radioisotopes were used to identify sentinel nodes. In case a macrometastatic lesion was found (>2mm) ALND was performed. Subsequent adequate systemic treatment and radiotherapy were administered in accordance with the pTNM status, biologic subtype and age. Results. A 3-year overall survival equaled 99.3% (SE 0.4%), recurrence-free survival was 99.2% (SE 0.4%). Survival of patients without nodal involvement reached 100%, whereas for patients with metastatic nodes it was 97.4% (SE 1.8%). The threshold for the number of the affected nodes significantly influencing survival equaled 1 (р=0,0187). Overall survival of patients with 0 to 1 positive lymph nodes was 99.7% (SE 0.3%), with more than 1 node involved - 95.7% (SE 0.3%) (р=0,00444). Conclusion. Overall 3-year survival of patients with early breast cancer approaches 100%. Sentinel lymph node biopsy allows avoiding unnecessary and traumatizing axillary dissection and improves the quality of life.

5 August 2023 in Tumors of female reproductive system
Verified
Journal Article
Open access
PDF file
VPV. I. Pavlova
V. I. Pavlova
YBYu. A. Belaya
Yu. A. Belaya
AVA. Yu. Vorontsov
A. Yu. Vorontsov
APA. A. Prishchepov
A. A. Prishchepov
SKS. M. Knyazev
S. M. Knyazev
NZN. A. Zakharova
N. A. Zakharova
Breast cancer is the most common cancer in women and one of the leading causes of death from cancer in Russia and most countries of the world. In countries with mammographic screening, there is a decrease in mortality from breast cancer. Introduction of mammographic image evaluation platforms into radiologist practice based on the work of artificial intelligence it allows not only to increase the coverage of the female population, but also to reduce the cost of screening, but it also increases the sensitivity and specificity of mammography as a method of breast cancer screening.The article presents the results of a study on the evaluation of mammographic images in women who have passed a preventive study using an artificial intelligence program.Within the framework of this project, mammographic images were analyzed using the service for viewing medical images “Celsus” in 8030 patients. The study assessed the age groups of 40-49 years, 50-59 years, 60 years and older. The average age of patients with suspected breast cancer was 54.8 years. Breast cancer was detected in 13 women (1.2 %), while the highest percentage of breast cancer was detected in the group with mammographic density D.